RecruitingBacteriuriaSpinal Cord InjuriesAsymptomatic Bacteriuria
Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 1b study to assess the safety, tolerability, PK, and PD of investigational phage therapy (IP) in adults with SCI and bladder colonization (ASB). It is a single-center, randomized, double-blind, placebo-controlled study in adults with SCI with neurogenic bladders and bacteriuria who use indwelling catheters, or who require intermittent catheterization for bladder drainage.
Sponsor: Barbara Trautner
You may qualify if…
- ✓ 1. Provision of signed and dated informed consent form.
- ✓ 2. Stated willingness to comply with all study procedures and availability for the duration of the study.
- ✓ 3. Adult (\> age 18) with a diagnosis of Spinal Cord Injury/Disease (SCI/D) and neurogenic bladder. Eligible participants may include inpatients in the SCI care unit or outpatients receiving care at participating sites, regardless of the underlying cause of SCI (e.g., trauma, tumors or demyelinating).
- ✓ 4. ASB with E. coli present in a quantity of ≥ 104 CFU/mL.
- ✓ 5. Require an indwelling (transurethral or suprapubic) or intermittent catheterization for bladder drainage.
- ✓ 6. Women of childbearing potential and men with female partners of childbearing potential must use two forms of effective contraception during the study and for two weeks afterwards.
- ✓ 7. Participant will be hospitalized during the 7 days of treatment or will be willing to attend clinic visits either (a) daily for the 7 days of treatment, or (b) on Day 1 and Day 7 of dosing. On Day 1, the participant will receive in-person training on instillation of the IP into the bladder.
You may not qualify if…
- ✕ 1. Unable to provide informed consent for themselves.
- ✕ 2. Received a new antibiotic expected to kill the Gram-negative organisms in the urine between initial enrollment urine culture and the time of randomization.
- ✕ 3. History of neutropenia, defined by ANC \< 1000 per µL within 6 months prior to screening.
- ✕ 4. History of organ transplantation.
- ✕ 5. Presence of a surgically modified bladder, except for a repaired ruptured bladder.
- ✕ 6. HIV with a CD4 count \< 200 cells per µL.
- ✕ 7. Unstable vital signs (e.g., fever, hypotension)
- ✕ 8. Symptoms of active urinary tract infection defined as fever, autonomic dysreflexia, generalized increase in spasticity, bladder spasms, new sweating, increase or change in lower abdominal pain, increase in burning or pain when passing urine, increase in burning or pain during catheterization, blood in the urine, or an increased sensation of urinary urgency (MedStar Health, Urinary Symptom Questionnaires for Neurogenic Bladder \[USQNB\]). The presence of any one of these symptoms, unless explained by a non-urinary or non-infectious condition, will be an exclusion criterion.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06559618 · last updated 2026-05-05